Histoplasmosis is a fungal infection caused by inhalation of spores from the fungus Histoplasma capsulatum. Our company specializes in developing therapy for infectious diseases such as histoplasmosis as we enable researchers and scientists who are involved with these infections by offering a wide range of tailored solutions.
Overview of Histoplasmosis
Histoplasmosis is a universal infection that has been reported in continents including America and Africa, it is said to affect nearly six out of every one hundred thousand people residing in areas of high prevalence. The infection can present mild respiratory issues or more dangerously progressive disseminated histoplasmosis with multi-organ involvement which can be fatal.
Fig.1 World map epidemiology of histoplasmosis. (Barros, N., et al., 2023)
Pathogenesis of Histoplasmosis
Histoplasmosis is known to be caused by the fungus Histoplasma capsulatum, which is found as a yeast in human tissues or as a mold in the environment. Its propensity to the conditions it flourishes in such as humid soil rich in bat or bird feces. Inhaling Histoplasma spores can cause a continuum of respiratory issues, they could be connected to systemic problems, and people who have weak immune systems are at a greater risk.
Fig.2 Pathogenesis of histoplasmosis. (Barros, N., et al., 2023)
Vaccine and Therapeutic Development for Histoplasmosis
Vaccine of Histoplasmosis
The construction of vaccines is significantly hampered by the fact that fungi can take on multiple forms. Currently, researchers are focusing on the identification and characterization of specific antigens that can trigger protective immune responses.
Therapeutic of Histoplasmosis
Histoplasmosis is now treated mainly with antifungal agents, particularly amphotericin B and its derivatives. This drug is effective against many variants of histoplasmosis, for instance, mild cases of pulmonary histoplasmosis or cases that are disseminated.
Our Services
We specialize in infectious disease therapy development by combining vaccines, and therapeutics development alongside infectious disease models that we offer. We also have integrated lab facilities and advanced equipment among other reagents and materials which we intend to improve the progress of the research for our clients.
Vaccine Development Platforms
Therapeutic Development Platforms
Infectious Disease Models
Many animal models can be utilized in the study of histoplasmosis, pathogenesis, immune response, and therapy methods of this fungal infection. Our company is able to provide you with diverse animal models so as to hasten your research.
Most animals are ordinarily infected with Histoplasma by either intranasal or intravenous injection to replicate natural infection routes. Immune response and antifungal therapeutics efficacy can be assessed by researchers.
Optional Models: Mouse model inoculated with Histoplasma capsulatum yeast, etc.
Through a comprehensive package of solutions, we enable researchers to create strategies for finding an understanding and therapy in diseases such as histoplasmosis. Should you wish to procure our services, please feel free to reach out to us for more information and precise quotes.
References
- Barros, Nicolas et al. "Pulmonary Histoplasmosis: A Clinical Update." Journal of fungi (Basel, Switzerland) 9.2 (2023): 236.
- Araúz, Ana Belén, and Padmasayee Papineni. "Histoplasmosis." Infectious disease clinics of North America 35.2 (2021): 471-491.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
